Art Rastinehad, DO, has been recognized as a 2026 Castle Connolly Top Doctor, marking his 12th year receiving this prestigious designation. Only 7 percent of U.S. licensed physicians are selected annually as Castle Connolly Top Doctors in their specialties and regions. Dr. Rastinehad serves as professor of urology and radiology, vice chair of urology at Northwell's Lenox Hill Hospital, and Northwell Health System director for prostate cancer. His clinical and research focus includes precision prostate cancer diagnosis, MRI-targeted biopsy, focal therapy, image-guided treatment, interventional urology, and prostate artery embolization for enlarged prostate or BPH.
Dr. Rastinehad emphasized that the recognition reflects the trust of patients and peers. He advocates for a personalized approach to prostate care, stating, "My goal is to help men make clear, informed decisions about prostate cancer, enlarged prostate, and urinary symptoms by coordinating the right evaluation and the most appropriate treatment options for each individual patient." He stresses that precision prostate care involves matching each patient to the correct diagnosis and treatment rather than using a one-size-fits-all method.
Dr. Rastinehad's research team has been instrumental in advancing image-guided prostate care. They contributed to early validation of MR/US fusion biopsy for prostate cancer detection in the United States and continue to develop focal therapy planning, minimally invasive treatments, and interventional options for BPH. Dr. Rastinehad is the first dual fellowship-trained urologic oncologist and interventional radiologist, having completed advanced training through the National Institutes of Health, the National Cancer Institute, and Northwell's North Shore University Hospital. This unique background enables him to combine cancer surgery, advanced imaging, and minimally invasive therapies in one practice.
Key achievements include being part of the first team to publish a series on prostate artery embolization in 2006, early validation of MR/US fusion biopsy, and serving as principal investigator in the development of UroNav/Philips MR/US fusion technology for biopsy and focal therapy planning. He is a founding executive board member of the Focal Therapy Society and has over 20 years of experience in prostate artery embolization and interventional urology. His ongoing work includes developing advanced image-guided planning and annotation tools for focal therapy.
Dr. Rastinehad's practice at the urology department at Lenox Hill Hospital provides advanced prostate care for men with elevated PSA, abnormal prostate MRI, localized prostate cancer, enlarged prostate or BPH, urinary symptoms, and complex treatment decisions. Castle Connolly Top Doctors are nominated by peer physicians and selected by a physician-led research team. Nominations are open to all board-certified MDs, DOs, and DPMs, and selection is based on criteria including medical education, training, hospital appointments, and disciplinary histories. Doctors cannot pay to be selected. For more information, visit castleconnolly.com.
